Non-Radiographic Axial Spondyloarthritis – Pipeline Review, 2019

Non-radiographic axial spondyloarthritis (nr-axSpA) is an autoimmune disorder which leads to arthritis of the pelvis and spine. Radiographic sacroiliitis is not exhibited by patients with non-radiographic axial spondylolysis. Stiffness and pain in the back, fatigue, pain in tendons & ligaments, and pain underneath the foot, and at the front of the chest are some of the symptoms associated with non-radiographic axial spondyloarthritis that usually begins between the age 15-45 years.

The blood test used to check for the presence of a gene HLA-B27 and imaging techniques such as MRI scan are methods used for the diagnosis of non-radiographic axial spondyloarthritis. According to National Ankylosing Spondylitis (NASS), it was estimated that around 7 in 10 people with nr-axSpA exhibit visible inflammation in the spine during MRI process and no inflammation would be exhibited by 3 in 10 people with non-radiographic axial spondyloarthritis. Physiotherapy and non-steroidal anti-inflammatory drugs are the first line of therapy for the treatment of non-radiographic axial spondylolysis that helps in the reduction of the pain associated with it. Additionally, biologic therapy is a relatively new treatment that could be very effective in the treatment of non-radiographic axial spondyloarthritis.

Many pharmaceutical companies have been focusing on studying and developing new treatment options for non-radiographic axial spondyloarthritis. For instance; Secukinumab, which is being studied by Novartis AG, is currently in phase-3 clinical trials for Study of Efficacy and Safety of Secukinumab in Patients with Non-radiographic axial spondyloarthritis

At present, around 69% of the pipeline candidates for Non-radiographic Axial Spondyloarthritis are in the phase-3 stage. More than half of the studies are sponsored by industry.

Report Description

The report on ‘Non-Radiographic Axial Spondyloarthritis – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Non-Radiographic Axial Spondyloarthritis. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Acromegaly.

The report on ‘Non-radiographic Axial Spondyloarthritis – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights about the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products forNon-radiographic Axial Spondyloarthritis


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players about R&D for Non-Radiographic Axial Spondyloarthritis


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyse the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary